source
- Verdiva ends mid-stage study of oral GLP-1 amid ‘market evolution’The candidate is an oral version of ecnoglutide, a subcutaneous formulation of which is approved in China for type 2 diabetes and weight management. Pfizer owns commercialization rights for ecnoglu…BioSpace · 6d ago↗ source
- Roche signs $1.2 bn obesity partnership with China's Rona Therapeutics, paying up to $100 m upfrontRoche announced its seventh China deal this year, partnering with RNA‑interference specialist Rona Therapeutics to target obesity. The collaboration licenses an ALK7 inhibition asset and includes…